VENTAB XL 75

Indications

• Bacterial infections
• Infections caused by susceptible organisms
• Prophylaxis in certain surgical procedures

Dosage

Children: Refer to the BNF for Children for specific dosing recommendations based on age, weight, and condition.

Adults: Refer to the BNF for specific dosages based on the condition being treated, severity of infection, and patient factors.

Mechanism of action

Release exerts its effects by inhibiting bacterial cell wall synthesis, leading to cell lysis and death. This mechanism is primarily mediated through the disruption of peptidoglycan cross-linking, which is essential for maintaining the structural integrity of bacterial cell walls.

Pharmacodynamics

The pharmacodynamics of Release involves its bactericidal action against a wide range of gram-positive and some gram-negative bacteria. The drug displays a time-dependent killing effect, meaning that its efficacy is related to the duration of exposure rather than the peak concentration achieved. Resistance to Release can develop through various mechanisms, including alterations in target sites or enzymatic degradation.

Pharmacokinetics

Release is absorbed and distributed throughout the body following administration. Peak plasma concentrations are typically achieved within a few hours. The drug is metabolized primarily in the liver, with metabolites excreted via the kidneys. The half-life of Release can vary depending on individual patient factors, including age, liver function, and concurrent medications.

Indications

• Major depressive disorder
• Generalized anxiety disorder
• Social anxiety disorder
• Panic disorder

Dosage

Children: Refer to BNF for Children for appropriate pediatric dosing information.

Adults: Refer to specific guidelines or BNF for detailed dosing information.

Mechanism of action

Venlafaxine exerts its pharmacological effects by inhibiting the reuptake of serotonin and norepinephrine in the synaptic cleft, thereby increasing the availability of these neurotransmitters at postsynaptic receptors. At lower doses, it primarily inhibits the reuptake of serotonin, while at higher doses, it also inhibits norepinephrine reuptake. This dual mechanism contributes to its antidepressant and anxiolytic properties.

Pharmacodynamics

The drug's action on serotonin and norepinephrine receptors leads to an enhancement of mood, reduction of anxiety, and improvement in overall mental health. The therapeutic effects can take several weeks to manifest, with initial improvements often seen in anxiety symptoms before mood elevation occurs. Venlafaxine may also influence other neurotransmitter systems indirectly, contributing to its efficacy.

Pharmacokinetics

Venlafaxine is well absorbed following oral administration, with peak plasma concentrations typically occurring within 2 hours for immediate-release formulations and 5 hours for extended-release forms. It undergoes extensive hepatic metabolism, primarily via cytochrome P450 2D6, to its active metabolite, O-desmethylvenlafaxine. The elimination half-life is approximately 5 hours for venlafaxine and 11 hours for its active metabolite. Renal excretion is the primary route for elimination, necessitating dosage adjustments in patients with renal impairment.

Contra-indications

• Hypersensitivity to venlafaxine or any of its components
• Concurrent use of monoamine oxidase inhibitors (MAOIs)
• Severe renal impairment

Adverse effects

• Nausea
• Dizziness
• Dry mouth
• Insomnia
• Somnolence
• Constipation
• Increased blood pressure
• Sexual dysfunction
• Sweating

Interactions

• Increased risk of serotonin syndrome with other serotonergic drugs
• Potentially increased effects with alcohol
• Caution with other medications affecting blood pressure
• May interact with anticoagulants, increasing bleed risk

Precautions

• Monitor blood pressure regularly during treatment
• Use with caution in patients with a history of seizures
• Risk of discontinuation syndrome if stopped abruptly
• May increase suicidal thoughts in young adults

Pregnancy

Venlafaxine should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus. Consult a healthcare provider for guidance.

Breast-feeding

It is not known whether venlafaxine is excreted in human milk. Caution is advised when administering to nursing mothers.

Storage

Store at room temperature, away from moisture and heat. Keep out of reach of children.

Formulations

• Tablets
• Extended-release capsules